Nutlin‐3a selects for cells harbouring TP 53 mutations

TP53 mutations occur in half of all human tumours. Mutagen‐induced or spontaneous TP53 mutagenesis can be studied in vitro using the human TP53 knock‐in (Hupki) mouse embryo fibroblast (HUF) immortalisation assay (HIMA). TP53 mutations arise in up to 30% of mutagen‐treated, immortalised HUFs; however, mutants are not identified until TP53 sequence analysis following immortalisation (2–5 months) and much effort is expended maintaining TP53‐WT cultures. In order to improve the selectivity of the HIMA for HUFs harbouring TP53 mutations, we explored the use of Nutlin‐3a, an MDM2 inhibitor that leads to stabilisation and activation of wild‐type (WT) p53. First, we treated previously established immortal HUF lines carrying WT or mutated TP53 with Nutlin‐3a to examine the effect on cell growth and p53 activation. Nutlin‐3a induced the p53 pathway in TP53‐WT HUFs and inhibited cell growth, whereas most TP53‐mutated HUFs were resistant to Nutlin‐3a. We then assessed whether Nutlin‐3a treatment could discriminate between TP53‐WT and TP53‐mutated cells during the HIMA (n = 72 cultures). As immortal clones emerged from senescent cultures, each was treated with 10 µM Nutlin‐3a for 5 days and observed for sensitivity or resistance. TP53 was subsequently sequenced from all immortalised clones. We found that all Nutlin‐3a‐resistant clones harboured TP53 mutations, which were diverse in position and functional impact, while all but one of the Nutlin‐3a‐sensitive clones were TP53‐WT. These data suggest that including a Nutlin‐3a counter‐screen significantly improves the specificity and efficiency of the HIMA, whereby TP53‐mutated clones are selected prior to sequencing and TP53‐WT clones can be discarded.

[1]  J. Kucab,et al.  TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts , 2016, DNA repair.

[2]  P. White,et al.  TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts , 2015, Mutation research.

[3]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[4]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[5]  J. Kucab,et al.  Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock‐in (Hupki) mouse embryo fibroblasts , 2012, Environmental and molecular mutagenesis.

[6]  R. Breitling,et al.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells , 2011, Cell Death and Disease.

[7]  C. Maki,et al.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.

[8]  J. Acebes,et al.  Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme , 2011, PloS one.

[9]  F. Westermann,et al.  Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.

[10]  J. Kucab,et al.  Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model , 2010, The FEBS journal.

[11]  M. Hollstein,et al.  How to become immortal: let MEFs count the ways , 2010, Aging.

[12]  M. Hollstein,et al.  Wild-type and Hupki (Human p53 Knock-in) Murine Embryonic Fibroblasts , 2010, The Journal of Biological Chemistry.

[13]  Baoying Huang,et al.  Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells , 2009, Molecular Cancer Research.

[14]  M. Hollstein,et al.  The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences. , 2008, Mutagenesis.

[15]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[16]  D. Beach,et al.  Cellular senescence bypass screen identifies new putative tumor suppressor genes , 2008, Oncogene.

[17]  H. Findley,et al.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.

[18]  Manuel Serrano,et al.  Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. , 2007, Cancer research.

[19]  L. R. Dearth,et al.  Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. , 2007, Carcinogenesis.

[20]  M. Hollstein,et al.  Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. , 2006, Mutation research.

[21]  M. Hollstein,et al.  p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. , 2005, Cancer research.

[22]  M. Hollstein,et al.  Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Kashiwazaki,et al.  Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry. , 2004, Human pathology.

[24]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[25]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Y. Xiong,et al.  Control of p53 ubiquitination and nuclear export by MDM2 and ARF. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  H. Kashiwazaki,et al.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. , 1999, Cancer research.

[28]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[29]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[30]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[31]  H. Green,et al.  QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES , 1963, The Journal of cell biology.

[32]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[33]  M. Hollstein,et al.  Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. , 2007, Genetic engineering.